GlassScriptPhysician profile
Tyler M Raile
NPI 1396924270
$156.25
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $72.97 · 2022: $55.39 · 2024: $27.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $27.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $27.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $37.79 | 2021 | |
| Organogenesis INC. | $27.89 | 2024 | |
| Amgen INC. | $24.15 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $18.30 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.81 | 2022 | |
| Pfizer INC. | $12.49 | 2021 | |
| Novo Nordisk INC | $11.77 | 2022 | |
| Lilly USA, LLC | $11.05 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Raile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.